Back to Results
First PageMeta Content
Vomiting / Ketones / GlaxoSmithKline / Ondansetron / Chemotherapy-induced nausea and vomiting / 5-HT3 antagonist / Postoperative nausea and vomiting / Chemotherapy / Nausea / Medicine / Antiemetics / Oncology


http://www.fda.gov/cder/foi/esum/2005/020007s035_Zofran_Pharm_Biopharm_BPCA.pdf
Add to Reading List

Document Date: 2006-11-13 08:05:24

Open Document

File Size: 39,35 KB

Share Result on Facebook

Company

GlaxoSmithKline / /

Country

United States / /

Event

FDA Phase / /

MedicalCondition

vomiting / pediatric cancer / postoperative nausea / cancer / post-operative nausea / adult cancer / chemotherapy-induced nausea / nausea / older cancer / /

MedicalTreatment

chemotherapy / surgery / /

Organization

ORM Division / Coagulation Drug Products OCPB Division / /

Person

Suresh Doddapaneni / Suliman I. Al-Fayoumi / /

Position

Team Leader / /

Product

Zofran / Ondansetron / SE5 / SE5-035 / S3A40319 / /

Technology

pharmacokinetics / chemotherapy / /

SocialTag